salicylic acid has been researched along with Keratosis, Actinic in 110 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Keratosis, Actinic: White or pink lesions on the arms, hands, face, or scalp that arise from sun-induced DNA DAMAGE to KERATINOCYTES in exposed areas. They are considered precursor lesions to superficial SQUAMOUS CELL CARCINOMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5%/salicylic acid 10% (5-FU/SA) topical solution has been included in the National Italian portfolio for lesion-directed treatment of grade I/II actinic keratosis (AKs) located on the face or scalp." | 7.96 | Treatment monitoring of 5-fluorouracil 0.5%/salicylic acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy. ( Benati, E; Condorelli, A; Cornacchia, L; Guiducci, L; Lai, M; Longo, C; Mirra, M; Pampena, R; Pellacani, G; Peris, K; Raucci, M, 2020) |
| "5%/salicylic acid 10% (5-FU/SA) in the treatment of isolated hyperkeratotic actinic keratosis lesions in Spain." | 7.81 | Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain. ( Brosa, M; Ferrándiz, C; Nieves, D; Plazas, MJ; Puig-Peiró, R, 2015) |
| "Photodynamic therapy with 5-methyl-aminolevulinate and photodynamic therapy with trichloroacetic acid 50% are the two techniques utilized in the management of actinic keratosis." | 7.81 | Comparative study of trichloroacetic acid vs. photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp. ( Boccaletti, V; Conti, ML; Cortelazzi, C; Di Nuzzo, S; Fabrizi, G; Feliciani, C; Montanari, P; Pagliarello, C; Zucchi, A, 2015) |
| "Both imiquimod and MAL-PDT were effective in the reduction in the number of AK." | 7.01 | Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp. ( Castagnetti, E; Cortelazzi, C; Di Nuzzo, S; Odorici, G; Pellacani, G, 2021) |
| "At 6-month posttreatment follow-up, recurrence of cleared lesions (no clinically visible lesions in treatment area) occurred in 39." | 6.80 | A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. ( Dirschka, T; Dominicus, R; Karl, L; Rodríguez, R; Simon, JC; Willers, C, 2015) |
| "Imiquimod 3." | 5.43 | Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type. ( Alomar, A; Aractingi, S; Dakovic, R; Dirschka, T; Gupta, G; Peris, K; Stockfleth, E, 2016) |
| " Protoporphyrin IX (PpIX) accumulation becomes lower after 3 h in pulse-PDT than in classical PDT, but pulse-PDT still has full treatment effect on actinic keratosis (AK)." | 5.27 | Protoporphyrin IX formation after application of methyl aminolevulinate on the face and scalp with and without prior curettage. ( Bieliauskiene, G; Heerfordt, IM; Wulf, HC, 2018) |
| "Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) is an effective treatment for actinic keratosis (AK) with some transient adverse events." | 5.19 | Topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid: randomized controlled trial with six months follow-up. ( Buinauskaite, E; Buinauskiene, J; Maciulaitis, R; Valiukeviciene, S, 2014) |
| " The articles were selected following a MEDLINE database search of the combined terms fluorouracil, salicylic acid and actinic keratosis which represent the peer review publications of clinical studies that primarily investigate the use of Actikerall in AK." | 4.93 | Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses. ( Azeredo, RR; Dirschka, T; Herranz, P; Morton, C; Roldán-Marín, R, 2016) |
| "5%/salicylic acid 10% (5-FU/SA) topical solution has been included in the National Italian portfolio for lesion-directed treatment of grade I/II actinic keratosis (AKs) located on the face or scalp." | 3.96 | Treatment monitoring of 5-fluorouracil 0.5%/salicylic acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy. ( Benati, E; Condorelli, A; Cornacchia, L; Guiducci, L; Lai, M; Longo, C; Mirra, M; Pampena, R; Pellacani, G; Peris, K; Raucci, M, 2020) |
| "To non-invasively assess the pharmacodynamic changes induced by treatment with low dose 5-fluorouracil and 10% salicylic acid by means of RCM and high-definition OCT in field cancerization and actinic keratosis." | 3.83 | Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. ( Alarcon, I; Malvehy, J; Montoya, J; Puig, S; Rodríguez-Azeredo, R, 2016) |
| "5%/salicylic acid 10% (5-FU/SA) in the treatment of isolated hyperkeratotic actinic keratosis lesions in Spain." | 3.81 | Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain. ( Brosa, M; Ferrándiz, C; Nieves, D; Plazas, MJ; Puig-Peiró, R, 2015) |
| "Photodynamic therapy with 5-methyl-aminolevulinate and photodynamic therapy with trichloroacetic acid 50% are the two techniques utilized in the management of actinic keratosis." | 3.81 | Comparative study of trichloroacetic acid vs. photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp. ( Boccaletti, V; Conti, ML; Cortelazzi, C; Di Nuzzo, S; Fabrizi, G; Feliciani, C; Montanari, P; Pagliarello, C; Zucchi, A, 2015) |
| "Pain is a frequent adverse event during photodynamic therapy, which can limit treatment acceptance." | 3.11 | Randomized controlled trial for evaluation of efficacy and pain during photodynamic therapy for actinic keratosis of face and scalp comparing two irradiation protocols. ( Ag, S; Er, O; Ha, M; Lpf, A; Mb, R; Mmc, M; Mr, G, 2022) |
| "Pretreatment with diclofenac for four weeks improved the clearance rate in one study (24." | 3.01 | Improving the efficacy of photodynamic therapy for actinic keratosis: A comprehensive review of pharmacological pretreatment strategies. ( Andersen, F; Bjerring, P; Haedersdal, M; Lerche, CM; Pihl, C, 2023) |
| "Both imiquimod and MAL-PDT were effective in the reduction in the number of AK." | 3.01 | Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp. ( Castagnetti, E; Cortelazzi, C; Di Nuzzo, S; Odorici, G; Pellacani, G, 2021) |
| "Pain was significantly higher during the second session (p = 0." | 2.90 | Single versus two-treatment schedule of methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient randomized trial. ( Fargnoli, MC; Gutiérrez García-Rodrigo, C; Pellegrini, C; Piccioni, A; Tambone, S, 2019) |
| " Adverse events were predominantly mild or moderate." | 2.84 | Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. ( Berman, B; Bukhalo, M; Hanke, CW; Pariser, DM; Siegel, D; Skov, T; Swanson, N; Villumsen, J; Weiss, JS, 2017) |
| "At 6-month posttreatment follow-up, recurrence of cleared lesions (no clinically visible lesions in treatment area) occurred in 39." | 2.80 | A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. ( Dirschka, T; Dominicus, R; Karl, L; Rodríguez, R; Simon, JC; Willers, C, 2015) |
| "However, pain is a major side-effect of this therapy." | 2.80 | Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial. ( Graf, B; Gruber, M; Hansen, E; Heinlin, J; Horner, C; Karrer, S; Kerscher, C; Klein, A; Koller, M; Landthaler, M; Szeimies, RM; Werner, A; Zeman, F, 2015) |
| "Cryosurgery is the most common treatment for actinic keratosis (AK) in the United States." | 2.79 | Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. ( Berman, B; Goldenberg, G; Goncalves, J; Hanke, CW; Knudsen, KM; Larsson, T; Skov, T; Swanson, N; Tyring, SK; Werschler, WP, 2014) |
| "Imiquimod 3." | 2.75 | Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp. ( Adams, M; Fein, MC; Furst, J; Kulp, J; Levy, S; Meng, TC, 2010) |
| "imiquimod 3." | 2.47 | Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. ( Gollnick, HP; Quist, SR, 2011) |
| "Actinic keratosis have a high risk of progression to a squamous cell carcinoma." | 1.91 | IGF1 synthesis after CO ( Cartocci, A; Cinotti, E; Fiorani, D; Rubegni, P; Trovato, E, 2023) |
| " In the future, further studies are needed to evaluate the chance of adjusting drug dosage according to patients' and actinic keratoses features." | 1.72 | Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study. ( Bianchi, L; Campione, E; Cosio, T; Di Prete, M; Di Raimondo, C; Diluvio, L; Gaeta Shumak, R; Garofalo, V; Geraci, F; Lambiase, S; Lanna, C; Lozzi, F, 2022) |
| " This prospective open-label observational single-arm study examined efficacy and safety of simulated daylight (SDL)-PDT using the IndoorLux® system in combination with 5-aminolevulinic acid gel (BF-200 ALA)." | 1.72 | No room for pain: A prospective study showing effective and nearly pain-free treatment of actinic keratosis with simulated daylight photodynamic therapy (SDL-PDT) using the IndoorLux® System in combination with BF-200 ALA (Ameluz®). ( Bai-Habelski, JC; Medrano, K; Palacio, A; Reinhold, U, 2022) |
| " Patient satisfaction was evaluated by questionnaire, and adverse effects were documented." | 1.72 | Efficacy and safety of a thermal fractional skin rejuvenation system (Tixel) for the treatment of facial and/or scalp actinic keratoses. ( Agmon, Y; Chorny, I; Friedland, R; Hodak, E; Klein, I; Lapidoth, M; Leshem, YA; Levi, A; Mimouni, D; Oren-Shabtai, M; Sloutsky, N; Snast, I, 2022) |
| "5% 5-fluorouracil solution in combination with 10% salicylic acid (low-dose 5-FU/SA) are mostly related to lesions appearing on the head and face." | 1.46 | Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study. ( Hadshiew, I; Melzer, A; Prechtl, A; Reinhold, U, 2017) |
| "Scalp melanoma has a worse prognosis than melanoma elsewhere, though the reasons for this are poorly understood." | 1.46 | Scalp melanoma: Distinctive high risk clinical and histological features. ( Kelly, JW; Mar, V; McLean, C; Pan, Y; Wolfe, R; Xie, C, 2017) |
| "Imiquimod 3." | 1.43 | Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type. ( Alomar, A; Aractingi, S; Dakovic, R; Dirschka, T; Gupta, G; Peris, K; Stockfleth, E, 2016) |
| "Patients suffering from chronic lymphocytic leukemia often develop actinic keratosis (AK) and squamous cell carcinoma in sun-exposed areas." | 1.43 | Ingenol Mebutate 500 μg for Treatment of the Scalp in Refractory Field Cancerization. ( Clayton, H; Gaide, O; Girardin, M; Kuonen, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.73) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.82) | 29.6817 |
| 2010's | 80 (72.73) | 24.3611 |
| 2020's | 25 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Garofalo, V | 1 |
| Geraci, F | 1 |
| Di Prete, M | 1 |
| Lanna, C | 1 |
| Lozzi, F | 1 |
| Cosio, T | 1 |
| Lambiase, S | 1 |
| Gaeta Shumak, R | 1 |
| Di Raimondo, C | 1 |
| Diluvio, L | 2 |
| Bianchi, L | 1 |
| Campione, E | 2 |
| Pihl, C | 1 |
| Lerche, CM | 1 |
| Andersen, F | 1 |
| Bjerring, P | 1 |
| Haedersdal, M | 2 |
| Pampena, R | 1 |
| Condorelli, A | 1 |
| Cornacchia, L | 1 |
| Guiducci, L | 1 |
| Raucci, M | 1 |
| Benati, E | 1 |
| Mirra, M | 1 |
| Peris, K | 7 |
| Lai, M | 1 |
| Pellacani, G | 3 |
| Longo, C | 1 |
| Ulrich, M | 2 |
| Reinhold, U | 3 |
| Falqués, M | 1 |
| Rodriguez Azeredo, R | 1 |
| Stockfleth, E | 9 |
| Iglesias-Puzas, A | 1 |
| Batalla, A | 1 |
| Suh-Oh, HJ | 1 |
| Flórez, A | 1 |
| Simon, JC | 2 |
| Dominicus, R | 1 |
| Karl, L | 1 |
| Rodríguez, R | 1 |
| Willers, C | 2 |
| Dirschka, T | 10 |
| Nieves, D | 1 |
| Puig-Peiró, R | 1 |
| Ferrándiz, C | 1 |
| Plazas, MJ | 1 |
| Brosa, M | 1 |
| Alarcon, I | 3 |
| Malvehy, J | 4 |
| Puig, S | 4 |
| Tolley, K | 2 |
| Kemmett, D | 1 |
| Thybo, S | 1 |
| Nasr, R | 1 |
| Smethurst, H | 1 |
| Szeimies, RM | 5 |
| Prechtl, A | 2 |
| Melzer, A | 2 |
| Sibbring, GC | 1 |
| Gholam, P | 1 |
| Fink, C | 1 |
| Bosselmann, I | 1 |
| Enk, AH | 1 |
| Montoya, J | 1 |
| Rodríguez-Azeredo, R | 1 |
| Nguyen, HP | 1 |
| Rivers, JK | 1 |
| Herranz, P | 1 |
| Morton, C | 2 |
| Azeredo, RR | 1 |
| Roldán-Marín, R | 2 |
| Hadshiew, I | 1 |
| Wojcik, R | 1 |
| Lowin, J | 1 |
| Vilardell, D | 1 |
| Maeso, S | 1 |
| Ruiz, L | 1 |
| Lear, JT | 2 |
| Schlaak, M | 1 |
| Kerl, H | 2 |
| Zwingers, T | 1 |
| THIERS, H | 1 |
| Jimenez, AR | 1 |
| Florell, SR | 1 |
| Donigan, JM | 1 |
| Er, O | 1 |
| Ag, S | 1 |
| Ha, M | 1 |
| Mb, R | 1 |
| Mmc, M | 1 |
| Mr, G | 1 |
| Lpf, A | 1 |
| Bai-Habelski, JC | 1 |
| Medrano, K | 1 |
| Palacio, A | 1 |
| Oren-Shabtai, M | 1 |
| Sloutsky, N | 1 |
| Lapidoth, M | 2 |
| Mimouni, D | 1 |
| Chorny, I | 1 |
| Snast, I | 1 |
| Leshem, YA | 1 |
| Friedland, R | 1 |
| Hodak, E | 1 |
| Klein, I | 1 |
| Agmon, Y | 1 |
| Levi, A | 1 |
| Miller, AC | 1 |
| Adjei, S | 1 |
| Temiz, LA | 1 |
| Tyring, SK | 2 |
| García-Gil, MF | 1 |
| Gracia-Cazaña, T | 1 |
| Cerro-Muñoz, P | 1 |
| Bernal-Masferrer, L | 1 |
| Navarro-Bielsa, A | 1 |
| Gilaberte, Y | 1 |
| Silic, K | 2 |
| Kammer, M | 1 |
| Sator, PG | 1 |
| Tanew, A | 2 |
| Radakovic, S | 2 |
| Trovato, E | 1 |
| Fiorani, D | 1 |
| Cartocci, A | 1 |
| Cinotti, E | 1 |
| Rubegni, P | 1 |
| Gioppo, IS | 1 |
| de Castro Martins, IM | 1 |
| Santos, SS | 1 |
| Preto, JFR | 1 |
| Miola, AC | 1 |
| Miot, HA | 1 |
| Gollnick, H | 1 |
| Ostendorf, R | 1 |
| Kunstfeld, R | 1 |
| Chabbert, C | 1 |
| Levy, M | 1 |
| Legrand, L | 1 |
| Mir-Bonafé, JF | 1 |
| Mir-Bonafé, M | 1 |
| Mozos, A | 1 |
| López-Sánchez, C | 1 |
| Piquero-Casals, J | 1 |
| de Dios-Velázquez, Á | 1 |
| Mir-Bonafé, JM | 1 |
| Rozas-Muñoz, E | 1 |
| Salido-Vallejo, R | 2 |
| Jiménez-Nájar, F | 1 |
| Garnacho-Sucedo, G | 1 |
| Vélez, A | 1 |
| Wójcicka, K | 1 |
| Szepietowski, JC | 1 |
| Abdalla, BMZ | 1 |
| Simas Pedreiro, B | 1 |
| Garcia Morales, A | 1 |
| Krutman Zveibil, D | 1 |
| Paschoal, FM | 1 |
| Bernardini, N | 1 |
| Proietti, I | 1 |
| Tolino, E | 1 |
| Zuber, S | 1 |
| Mambrin, A | 1 |
| Balduzzi, V | 1 |
| Marchesiello, A | 1 |
| Anzalone, A | 1 |
| Colapietra, D | 1 |
| Potenza, C | 1 |
| Skroza, N | 1 |
| Meierhofer, C | 1 |
| Urban, MV | 1 |
| Berman, B | 6 |
| Bukhalo, M | 2 |
| Hanke, CW | 5 |
| Jarner, MF | 1 |
| Larsson, T | 3 |
| Siegel, DM | 1 |
| Skov, T | 4 |
| Cortelazzi, C | 2 |
| Odorici, G | 1 |
| Castagnetti, E | 1 |
| Di Nuzzo, S | 2 |
| Blauvelt, A | 1 |
| Kempers, S | 1 |
| Lain, E | 1 |
| Schlesinger, T | 1 |
| Tyring, S | 1 |
| Forman, S | 1 |
| Ablon, G | 1 |
| Martin, G | 1 |
| Wang, H | 1 |
| Cutler, DL | 1 |
| Fang, J | 1 |
| Kwan, MR | 1 |
| Arisi, M | 2 |
| Rossi, MT | 1 |
| Spiazzi, L | 1 |
| Guasco Pisani, E | 1 |
| Venturuzzo, A | 1 |
| Rovati, C | 1 |
| Tomasi, C | 1 |
| Venturini, M | 1 |
| Calzavara-Pinton, PG | 1 |
| Fine, JD | 1 |
| Dewan, A | 1 |
| Miller, JL | 1 |
| Bucko, AD | 1 |
| Jarratt, M | 1 |
| Stough, DB | 1 |
| Kyhl, L | 1 |
| Villumsen, J | 2 |
| Hall, A | 1 |
| Dréno, B | 1 |
| Cerio, R | 1 |
| Nart, IF | 1 |
| de Casas, AR | 1 |
| Kaleci, S | 1 |
| Bower, C | 1 |
| Swanson, N | 6 |
| Pariser, DM | 1 |
| Weiss, JS | 1 |
| Siegel, D | 1 |
| Ortega Del Olmo, R | 1 |
| Sotiriou, E | 4 |
| Evangelou, G | 1 |
| Papadavid, E | 1 |
| Apalla, Z | 4 |
| Vrani, F | 2 |
| Vakirlis, E | 2 |
| Panagiotou, M | 1 |
| Stefanidou, M | 1 |
| Pombou, T | 1 |
| Krasagakis, K | 1 |
| Rigopoulos, D | 1 |
| Ioannides, D | 4 |
| Galimberti, GN | 1 |
| Harwood, CA | 1 |
| Serra-Guillén, C | 2 |
| Østerdal, ML | 1 |
| Carbone, A | 1 |
| Sperduti, I | 1 |
| De Simone, P | 1 |
| Piemonte, P | 1 |
| Ferrari, A | 1 |
| Buccini, P | 1 |
| Silipo, V | 1 |
| Iorio, A | 1 |
| Frascione, P | 1 |
| Eibenschutz, L | 1 |
| Bagatin, E | 1 |
| Heerfordt, IM | 1 |
| Bieliauskiene, G | 1 |
| Wulf, HC | 1 |
| Lazaridou, E | 1 |
| Sideris, N | 1 |
| Kirmanidou, E | 1 |
| Lallas, A | 1 |
| Nagore, E | 1 |
| Bancalari, E | 1 |
| Kindem, S | 1 |
| Sanmartín, O | 1 |
| Llombart, B | 1 |
| Requena, C | 1 |
| Serra-Guillén, I | 1 |
| Calomarde, L | 1 |
| Diago, A | 1 |
| Bernia, E | 1 |
| Guillén, C | 1 |
| Schmitz, L | 1 |
| Stücker, M | 1 |
| Gambichler, T | 1 |
| Giuffrida, R | 1 |
| Borgia, F | 1 |
| Cannavò, SP | 1 |
| Vicentini, C | 1 |
| Vignion-Dewalle, AS | 1 |
| Thecua, E | 1 |
| Lecomte, F | 1 |
| Maire, C | 1 |
| Deleporte, P | 1 |
| Béhal, H | 1 |
| Kerob, D | 1 |
| Duhamel, A | 1 |
| Mordon, S | 1 |
| Mortier, L | 1 |
| Ruini, C | 1 |
| Hartmann, D | 1 |
| Bastian, M | 1 |
| Ruzicka, T | 1 |
| French, LE | 1 |
| Berking, C | 1 |
| von Braunmühl, T | 1 |
| Sousa, ACDS | 1 |
| Campos, MAC | 1 |
| Baptista, AM | 1 |
| Menezes, NMBVN | 1 |
| Zavattaro, E | 1 |
| Veronese, F | 1 |
| Landucci, G | 1 |
| Tarantino, V | 1 |
| Savoia, P | 1 |
| Ramelyte, E | 1 |
| Imhof, L | 1 |
| Morton, CA | 1 |
| Balcere, A | 1 |
| Rone Kupfere, M | 1 |
| Čēma, I | 1 |
| Krūmiņa, A | 1 |
| Gutiérrez García-Rodrigo, C | 1 |
| Pellegrini, C | 1 |
| Piccioni, A | 2 |
| Tambone, S | 3 |
| Fargnoli, MC | 3 |
| Dominguez-Cruz, J | 1 |
| Ruiz-Villaverde, R | 1 |
| Rizvi, SM | 1 |
| Veierød, MB | 1 |
| Mørk, G | 1 |
| Helsing, P | 1 |
| Gjersvik, P | 1 |
| Tzogani, K | 1 |
| Straube, M | 1 |
| Hoppe, U | 1 |
| Kiely, P | 1 |
| O'Dea, G | 1 |
| Enzmann, H | 1 |
| Salmon, P | 1 |
| Salmonson, T | 1 |
| Pignatti, F | 1 |
| Tallon, B | 1 |
| Turnbull, N | 1 |
| Smith, CC | 2 |
| Kaur, M | 2 |
| Goldenberg, G | 3 |
| Buinauskaite, E | 1 |
| Maciulaitis, R | 1 |
| Buinauskiene, J | 1 |
| Valiukeviciene, S | 1 |
| Puviani, M | 1 |
| Barcella, A | 1 |
| Milani, M | 1 |
| Werschler, WP | 1 |
| Knudsen, KM | 2 |
| Goncalves, J | 1 |
| Iglesias-García, P | 1 |
| Díaz, A | 1 |
| Vegter, S | 1 |
| Gupta, G | 3 |
| Aractingi, S | 3 |
| Alomar, A | 3 |
| Dakovic, R | 3 |
| Klein, A | 1 |
| Karrer, S | 1 |
| Horner, C | 1 |
| Werner, A | 1 |
| Heinlin, J | 1 |
| Zeman, F | 1 |
| Koller, M | 1 |
| Landthaler, M | 1 |
| Gruber, M | 1 |
| Graf, B | 1 |
| Hansen, E | 1 |
| Kerscher, C | 1 |
| Boccaletti, V | 1 |
| Zucchi, A | 1 |
| Conti, ML | 1 |
| Montanari, P | 1 |
| Feliciani, C | 1 |
| Fabrizi, G | 1 |
| Pagliarello, C | 1 |
| Karmisholt, KE | 1 |
| Bettencourt, MS | 1 |
| Capizzi, R | 1 |
| Jambusaria-Pahlajani, A | 1 |
| Ortman, S | 1 |
| Schmults, CD | 1 |
| Liang, C | 1 |
| Xie, C | 1 |
| Pan, Y | 1 |
| McLean, C | 1 |
| Mar, V | 1 |
| Wolfe, R | 1 |
| Kelly, JW | 1 |
| Ricci, F | 1 |
| Neri, L | 1 |
| Fania, L | 1 |
| Guerriero, C | 1 |
| Gaide, O | 1 |
| Clayton, H | 1 |
| Girardin, M | 1 |
| Kuonen, F | 1 |
| Zane, C | 1 |
| Fabiano, A | 1 |
| Calzavara-Pinton, P | 1 |
| Shabbir, AQ | 1 |
| MacNeil, T | 1 |
| Gandy, J | 1 |
| Labadie, B | 1 |
| Bierman, D | 1 |
| Zachary, C | 1 |
| Siller, G | 1 |
| Gebauer, K | 1 |
| Welburn, P | 1 |
| Katsamas, J | 1 |
| Ogbourne, SM | 1 |
| Schmid-Wendtner, MH | 1 |
| Wendtner, CM | 1 |
| Chovarda, E | 2 |
| Lefaki, I | 1 |
| Devliotou-Panagiotidou, D | 1 |
| Paternò, EJ | 1 |
| Chimenti, S | 1 |
| Beer, KR | 1 |
| Wu, J | 1 |
| Rosen, T | 1 |
| Levy, S | 4 |
| Abramovits, W | 1 |
| Kulp, J | 3 |
| Rigel, DS | 1 |
| Fein, MC | 1 |
| Adams, M | 1 |
| Furst, J | 1 |
| Meng, TC | 1 |
| Stollery, N | 1 |
| Quist, SR | 1 |
| Gollnick, HP | 1 |
| Bruce, S | 1 |
| Goussi, C | 1 |
| Trigoni, A | 1 |
| Göksu, Y | 1 |
| Hofbauer, G | 1 |
| Serra, A | 1 |
| Nowak, A | 1 |
| Adatto, M | 1 |
| Halachmi, S | 1 |
| GLUSHIKHIN, MA | 1 |
| PICKRELL, K | 1 |
| MATTON, G | 1 |
| HUGER, W | 1 |
| POUND, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis[NCT01358851] | Phase 2 | 67 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma[NCT01453179] | Phase 4 | 221 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp[NCT03285477] | Phase 3 | 351 participants (Actual) | Interventional | 2017-09-18 | Completed | ||
| A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp[NCT03285490] | Phase 3 | 351 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| A Phase 2, Single-Arm, Open-Label, Single Center Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects With Superficial Basal Cell Carcinoma (sBCC) on the Neck, Trunk, or Extremities (Excluding Axilla, Anogenital, and Face/Scal[NCT05713760] | Phase 2 | 10 participants (Anticipated) | Interventional | 2023-04-17 | Recruiting | ||
| A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp[NCT01541553] | Phase 3 | 367 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT)[NCT02716714] | Phase 4 | 77 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial[NCT03642535] | Phase 4 | 300 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment With Imiquimod Creams for Actinic Keratoses[NCT00603798] | Phase 3 | 490 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial[NCT04219358] | Phase 1 | 49 participants (Actual) | Interventional | 2019-03-23 | Terminated (stopped due to Study terminated because of COVID19 pandemics.) | ||
| A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Four Weeks of Treatment With Imiquimod Creams for Actinic Keratoses[NCT00605176] | Phase 3 | 479 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705[NCT00668733] | 179 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ECG parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals. Clinical significance was determined by the investigator. (NCT03285477)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| KX2-391 Ointment 1% | 0 |
A physical examination included weight and height measurements was performed. Clinical significance was determined by the investigator. (NCT03285477)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| KX2-391 Ointment 1% | 0 |
Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature. Clinical significance was determined by the investigator. (NCT03285477)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| KX2-391 Ointment 1% | 0 |
Complete clearance rate was defined as the percentage of participants at Day 57 with no clinically visible AK lesions in the treatment area. (NCT03285477)
Timeframe: Day 57
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 5 |
| KX2-391 Ointment 1% | 44 |
Partial clearance rate of AK lesions was defined as the percentage of participants with a greater than or equal to (>=) 75% reduction in the number of AK lesions identified at Baseline (Day 1 predose) in the treatment area. (NCT03285477)
Timeframe: Day 57
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16 |
| KX2-391 Ointment 1% | 68 |
An AE was defined as any untoward medical occurrence in participant which does not necessarily have causal relationship with treatment. An AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal product, whether or not considered related to medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death; was life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in patient hospitalization; was congenital anomaly/birth defect or otherwise considered medically important. TEAEs (serious and non-serious) were defined as either those AEs with onset after first dose or those pre-existing AEs that worsen after first dose. Events of special interest included skin cancers (including basal cell carcinoma, squamous cell carcinoma, melanoma and their location and treatment area), ocular exposure, overdose, and pregnancy. (NCT03285477)
Timeframe: Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Participants with AE | Participants with any TEAE | Participants with SAE | Participants with events of special interest | |
| KX2-391 Ointment 1% | 66 | 57 | 0 | 5 |
| Placebo | 62 | 57 | 2 | 4 |
An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death; was life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in patient hospitalization; was congenital anomaly/birth defect or otherwise considered medically important. Events of special interest included skin cancers (including basal cell carcinoma, squamous cell carcinoma, melanoma and their location and treatment area), ocular exposure, overdose, and pregnancy. (NCT03285477)
Timeframe: From Day 57 up to 12-months post-Day 57
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Participants with any AE | Participants with any SAE | Participants with events of special interest | |
| KX2-391 Ointment 1% | 4 | 1 | 0 |
| Placebo | 0 | 0 | 0 |
Assessed laboratory parameters included hematology, blood chemistry and urinalysis. Clinical significance and abnormal observations were determined by the investigator. (NCT03285477)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Hematology | Blood chemistry | Urinalysis | |
| KX2-391 Ointment 1% | 0 | 1 | 3 |
| Placebo | 0 | 1 | 0 |
Maximal post baseline LSR was defined as the highest grade of any LSR reported at any post baseline visits for a participant. The LSR assessment was an Investigator's (or sub-investigator's) assessment of the following signs on the treatment area: erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. The LSRs were graded on a 4-point scale ranging from 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). (NCT03285477)
Timeframe: Day 57
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema-Grade 0 | Erythema-Grade 1 | Erythema-Grade 2 | Erythema-Grade 3 | Flaking/Scaling-Grade 0 | Flaking/Scaling-Grade 1 | Flaking/Scaling-Grade 2 | Flaking/Scaling-Grade 3 | Crusting-Grade 0 | Crusting-Grade 1 | Crusting-Grade 2 | Crusting-Grade 3 | Swelling-Grade 0 | Swelling-Grade 1 | Swelling-Grade 2 | Swelling-Grade 3 | Vesiculation/Pustulation-Grade 0 | Vesiculation/Pustulation-Grade 1 | Vesiculation/Pustulation-Grade 2 | Vesiculation/Pustulation-Grade 3 | Erosion/Ulceration-Grade 0 | Erosion/Ulceration-Grade 1 | Erosion/Ulceration-Grade 2 | Erosion/Ulceration-Grade 3 | |
| KX2-391 Ointment 1% | 6 | 48 | 116 | 5 | 16 | 70 | 78 | 11 | 84 | 69 | 20 | 2 | 107 | 55 | 12 | 1 | 158 | 14 | 2 | 1 | 155 | 15 | 5 | 0 |
| Placebo | 81 | 84 | 11 | 0 | 72 | 90 | 14 | 0 | 140 | 33 | 3 | 0 | 163 | 12 | 1 | 0 | 174 | 2 | 0 | 0 | 168 | 8 | 0 | 0 |
Absence or presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment area were assessed. (NCT03285477)
Timeframe: Baseline (Day 1 predose), Days 5, 8, 15, 29 and 57
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypopigmentation: Baseline | Hypopigmentation: Day 5 | Hypopigmentation: Day 8 | Hypopigmentation: Day 15 | Hypopigmentation: Day 29 | Hypopigmentation: 57 | Hyperpigmentation: Baseline | Hyperpigmentation: Day 5 | Hyperpigmentation: Day 8 | Hyperpigmentation: Day 15 | Hyperpigmentation: Day 29 | Hyperpigmentation: Day 57 | Scarring: Baseline | Scarring: Day 5 | Scarring: Day 8 | Scarring: Day 15 | Scarring: Day 29 | Scarring: Day 57 | |
| KX2-391 Ointment 1% | 21 | 11 | 10 | 12 | 17 | 13 | 22 | 18 | 17 | 20 | 18 | 12 | 12 | 8 | 7 | 8 | 9 | 7 |
| Placebo | 21 | 19 | 21 | 23 | 23 | 20 | 27 | 24 | 23 | 26 | 25 | 23 | 10 | 8 | 9 | 7 | 7 | 7 |
Overall the change from baseline in lesion count at each visit were summarized and reported using descriptive statistics by treatment location (face or scalp). (NCT03285477)
Timeframe: Days 8, 15, 29 and 57
| Intervention | lesion count (Median) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 29 | Day 57 | |
| KX2-391 Ointment 1% | -1.0 | -4.0 | -4 | -5.0 |
| Placebo | 0.0 | 0.0 | -1.0 | -1.0 |
Recurrence rate was estimated based on Kaplan-Meier method, with recurrence define as appearance of any AK lesions in the treatment area, including those recurred or newly identified. (NCT03285477)
Timeframe: 3, 6, 9 and 12 months post-Day 57
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| 3 Months Post-Day 57 | 6 Months Post-Day 57 | 9 Months Post-Day 57 | 12 months Post-Day 57 | |
| KX2-391 Ointment 1% | 33 | 30 | 33 | 18 |
ECG parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals. Clinical significance was determined by the investigator. (NCT03285490)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| KX2-391 Ointment 1% | 0 |
A physical examination included weight and height measurements was performed. Clinical significance was determined by the investigator. (NCT03285490)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| KX2-391 Ointment 1% | 0 |
Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature. Clinical significance was determined by the investigator. (NCT03285490)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| KX2-391 Ointment 1% | 0 |
Complete clearance rate was defined as the percentage of participants at Day 57 with no clinically visible AK lesions in the treatment area. (NCT03285490)
Timeframe: Day 57
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13 |
| KX2-391 Ointment 1% | 54 |
Partial clearance rate of AK lesions was defined as the percentage of participants with a greater than or equal to (>=) 75% reduction in the number of AK lesions identified at Baseline (Day 1 predose) in the treatment area. (NCT03285490)
Timeframe: Day 57
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20 |
| KX2-391 Ointment 1% | 76 |
An AE was defined as any untoward medical occurrence in participant which does not necessarily have causal relationship with treatment. An AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal product, whether or not considered related to medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death; was life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in patient hospitalization; was congenital anomaly/birth defect or otherwise considered medically important. TEAEs (serious and non-serious) were defined as either those AEs with onset after first dose or those pre-existing AEs that worsen after first dose. Events of special interest included skin cancers (including basal cell carcinoma, squamous cell carcinoma, melanoma and their location and treatment area), ocular exposure, overdose, and pregnancy. (NCT03285490)
Timeframe: Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Participants with AE | Participants with any TEAE | Participants with any SAE | Participants with events of special interest | |
| KX2-391 Ointment 1% | 71 | 67 | 1 | 4 |
| Placebo | 73 | 67 | 4 | 4 |
An AE was defined as any untoward medical occurrence in participant which does not necessarily have causal relationship with treatment. An AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with use of medicinal product, whether or not considered related to medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death; was life threatening; required persistent/significant disability/incapacity; resulted in initial or prolonged in patient hospitalization; was congenital anomaly/birth defect or otherwise considered medically important. Events of special interest included skin cancers (including basal cell carcinoma, squamous cell carcinoma, melanoma and their location and treatment area), ocular exposure, overdose, and pregnancy. (NCT03285490)
Timeframe: From Day 57 up to 12-months post-Day 57
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Participants with any AE | Participants with any SAE | Participants with events of special interest | |
| KX2-391 Ointment 1% | 2 | 0 | 0 |
| Placebo | 0 | 0 | 1 |
Assessed laboratory parameters included hematology, blood chemistry and urinalysis. Clinical significance and abnormal observations were determined by the investigator. (NCT03285490)
Timeframe: From Baseline (Day 1 predose) up to Day 57
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Hematology | Blood chemistry | Urinalysis | |
| KX2-391 Ointment 1% | 0 | 0 | 1 |
| Placebo | 0 | 4 | 0 |
Maximal post baseline LSR was defined as the highest grade of any LSR reported at any post baseline visits for a participant. The LSR assessment was an Investigator's (or sub-investigator's) assessment of the following signs on the treatment area: erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. The LSRs were graded on a 4-point scale ranging from 0=absent, 1=mild (slightly, barely perceptible), 2=moderate (distinct presence), and 3=severe (marked, intense). (NCT03285490)
Timeframe: Day 57
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erythema-Grade 0 | Erythema-Grade 1 | Erythema-Grade 2 | Erythema-Grade 3 | Flaking/Scaling-Grade 0 | Flaking/Scaling-Grade 1 | Flaking/Scaling-Grade 2 | Flaking/Scaling-Grade 3 | Crusting-Grade 0 | Crusting-Grade 1 | Crusting-Grade 2 | Crusting-Grade 3 | Swelling-Grade 0 | Swelling-Grade 1 | Swelling-Grade 2 | Swelling-Grade 3 | Vesiculation/Pustulation-Grade 0 | Vesiculation/Pustulation-Grade 1 | Vesiculation/Pustulation-Grade 2 | Vesiculation/Pustulation-Grade 3 | Erosion/Ulceration-Grade 0 | Erosion/Ulceration-Grade 1 | Erosion/Ulceration-Grade 2 | Erosion/Ulceration-Grade 3 | |
| KX2-391 Ointment 1% | 3 | 47 | 111 | 17 | 8 | 60 | 90 | 20 | 92 | 51 | 30 | 5 | 110 | 47 | 20 | 1 | 166 | 11 | 0 | 1 | 156 | 18 | 4 | 0 |
| Placebo | 79 | 81 | 13 | 0 | 82 | 69 | 21 | 1 | 148 | 19 | 6 | 0 | 169 | 4 | 0 | 0 | 172 | 1 | 0 | 0 | 171 | 2 | 0 | 0 |
Absence or presence of pigmentation (i.e., hypopigmentation and hyperpigmentation) and scarring in the treatment area were assessed. (NCT03285490)
Timeframe: Baseline (Day 1 predose), Days 5, 8, 15, 29 and 57
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypopigmentation: Baseline | Hypopigmentation: Day 5 | Hypopigmentation: Day 8 | Hypopigmentation: Day 15 | Hypopigmentation: Day 29 | Hypopigmentation: Day 57 | Hyperpigmentation: Baseline | Hyperpigmentation: Day 5 | Hyperpigmentation: Day 8 | Hyperpigmentation: Day 15 | Hyperpigmentation: Day 29 | Hyperpigmentation: Day 57 | Scarring: Baseline | Scarring: Day 5 | Scarring: Day 8 | Scarring: Day 15 | Scarring: Day 29 | Scarring: Day 57 | |
| KX2-391 Ointment 1% | 30 | 28 | 30 | 31 | 32 | 29 | 36 | 33 | 34 | 32 | 29 | 25 | 11 | 13 | 11 | 9 | 9 | 9 |
| Placebo | 26 | 26 | 23 | 21 | 21 | 21 | 33 | 30 | 30 | 27 | 24 | 25 | 9 | 8 | 8 | 9 | 8 | 10 |
Overall the change from baseline in lesion count at each visit were summarized and reported using descriptive statistics by treatment location (face or scalp). (NCT03285490)
Timeframe: Days 8, 15, 29 and 57
| Intervention | lesion count (Median) | |||
|---|---|---|---|---|
| Day 8 | Day 15 | Day 29 | Day 57 | |
| KX2-391 Ointment 1% | -1.0 | -4.0 | -5.0 | -5.0 |
| Placebo | 0.0 | -1.0 | -1.0 | -1.0 |
Recurrence rate was estimated based on Kaplan-Meier method, with recurrence define as appearance of any AK lesions in the treatment area, including those recurred or newly identified. (NCT03285490)
Timeframe: 3, 6, 9 and 12 months post-Day 57
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| 3 months post-Day 57 | 6 months post-Day 57 | 9 months post-Day 57 | 12 months post-Day 57 | |
| KX2-391 Ointment 1% | 27 | 31 | 27 | 23 |
To determine the 11-week rate of complete clearance of AKs (defined as no clinically visible AKs) in the selected treatment area using sequential cryotherapy and field treatment with PEP005 Gel compared to cryotherapy alone. (NCT01541553)
Timeframe: 11 weeks
| Intervention | participants (Number) |
|---|---|
| PEP005 Gel, 0.015% | 101 |
| Vehicle Gel | 80 |
Partial clearance of AKs at Week 11, defined as 75% or greater reduction from baseline in the number of clinically visible AKs in the selected treatment area at Week 11 (NCT01541553)
Timeframe: Week 11
| Intervention | participants (Number) |
|---|---|
| PEP005 Gel, 0.015% | 130 |
| Vehicle Gel | 109 |
Percentage change from baseline in number of AKs at Week 11 (NCT01541553)
Timeframe: Baseline to week 11
| Intervention | percentage of change (Mean) |
|---|---|
| PEP005 Gel, 0.015% | 81.1 |
| Vehicle Gel | 74.1 |
Percentage change from baseline in the number of actinic keratiosis(AK) lesions in the selected treatment area on Day 57 was analyzed. (NCT02716714)
Timeframe: Baseline and Day 57
| Intervention | percentage change (Mean) |
|---|---|
| Ingenol Mebutate Gel 0.015% | -80.08 |
| Ingenol Mebutate Gel 0.05% | -88.89 |
Percentage change from baseline in the number of actinic keratiosis(AK) lesions at Month 6 in the selected treatment area in complete clearance(CC) Group was analyzed. (NCT02716714)
Timeframe: at 6 months from baseline
| Intervention | Percentage change (Mean) |
|---|---|
| Ingenol Mebutate Gel 0.015% | -88.65 |
| Ingenol Mebutate Gel 0.05% | -85.71 |
Time to relapse in complete clearance(CC) Group was analyzed. Median survival time with 95% confidence interval was calculated by Kaplan-Meier method. (NCT02716714)
Timeframe: at 6 months
| Intervention | days (Median) |
|---|---|
| Ingenol Mebutate Gel 0.015% | NA |
| Ingenol Mebutate Gel 0.05% | 203 |
Skindex-29 is a self-administered QoL questionnaire comprised of 29 items scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 items), symptomatic (7 items), and functional (12 items), with domain scores ranging from 0 to 40, 28, and 48, respectively. Lower scores for each of the domains represents a better Quality of life. (NCT02716714)
Timeframe: at 29 and 57 days from baseline
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emotions(Baseline) | Emotions(Day 29) | Emotions(Day 57) | Emotions(Day 29-Baseline) | Emotions(Day 57-Baseline) | Symptoms(Baseline) | Symptoms(Day 29) | Symptoms(Day 57) | Symptoms(Day 29-Baseline) | Symptoms(Day 57-Baseline) | Functioning(Baseline) | Functioning(Day 29) | Functioning(Day 57) | Functioning(Day 29-Baseline) | Functioning(Day 57-Baseline) | |
| Ingenol Mebutate Gel 0.015% | 20.57 | 21.21 | 15.28 | -0.42 | -6.46 | 16.45 | 20.16 | 12.41 | 3.09 | -4.76 | 8.54 | 17.10 | 10.58 | 8.02 | 1.45 |
| Ingenol Mebutate Gel 0.05% | 27.22 | 12.50 | 12.78 | -14.72 | -14.44 | 31.35 | 13.89 | 12.70 | -17.46 | -18.65 | 13.43 | 5.56 | 3.24 | -7.87 | -10.19 |
The count of participants in complete clearance(CC) group and Non-CC group who administered medication for actinic keratosis on the selected treatment area after Day 57 was collected. (NCT02716714)
Timeframe: from 57 days to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Fluorouracil | Imiquimod | |
| CC Group | 0 | 1 |
| Non-CC Group | 1 | 0 |
The count of participants in complete clearance(CC) group and Non-CC group who received non-drug treatment/surgery for actinic keratosis on the selected treatment area after Day 57 was collected. (NCT02716714)
Timeframe: from 57 days to 6 months
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Skin cryotherapy | Photodynamic therapy | Phototherapy | Skin lesion excision | Wound treatment | Biopsy skin | |
| CC Group | 5 | 0 | 0 | 1 | 1 | 0 |
| Non-CC Group | 4 | 1 | 1 | 0 | 0 | 1 |
Recurrence rate in complete clearance(CC) group was analyzed. (NCT02716714)
Timeframe: at 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Recurrence rate | Censored | |
| Ingenol Mebutate Gel 0.015% | 5 | 42 |
| Ingenol Mebutate Gel 0.05% | 2 | 5 |
Sustained Complete Clearance means that Complete Clearance was maintained until Month 6 in complete clearance (CC) group and sustained complete clearance(CC) rate at month 6 for complete clearance(CC) group was analyzed. (NCT02716714)
Timeframe: at 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Sustained CC | Recurrence | |
| Ingenol Mebutate Gel 0.015% | 42 | 5 |
| Ingenol Mebutate Gel 0.05% | 6 | 1 |
"Participants personally completed the tool to evaluate satisfaction with drug treatment. It consisted of 4 areas of Effectiveness, side effect, convenience, and global satisfaction, with a total of 14 sub-items. The full mark is 100, and it is divided in four stages as follows.~Very good: 76 -100 score~Good: 51-75 score~Not bad: 26-50 score~Bad: 0-25 score Scores for each area ranged from 0 to 100, with higher scores indicating that fewer side effects had occurred and greater treatment satisfaction." (NCT02716714)
Timeframe: at 29 and 57 days from baseline
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Effectiveness(Day 29) | Effectiveness(Day 57) | Side-effect(Day 29) | Side-effect(Day 57) | Convenience(Day 29) | Convenience(Day 57) | Global satisfaction(Day 29) | Global satisfaction(Day 57) | |
| Ingenol Mebutate Gel 0.015% | 57.62 | 62.67 | 84.48 | 89.26 | 60.75 | 65.10 | 59.22 | 60.60 |
| Ingenol Mebutate Gel 0.05% | 61.11 | 70.37 | 91.67 | 91.41 | 61.11 | 65.43 | 65.08 | 63.49 |
The investigator rated the subject's Cosmetic Outcomes Assessment(COA) using 5 grades (Very good, Good, No change, Bad, Very bad), and results were as follows. (NCT02716714)
Timeframe: at 29 and 57 days from baseline
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2972105067 | Day 2972105068 | Day 5772105067 | Day 5772105068 | |||||||||||||||||
| Very good | Good | No change | Bad | Very bad | ||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 16 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.05% | 3 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 33 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.05% | 4 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 5 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.05% | 1 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 8 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 0 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 17 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 39 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.05% | 5 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 6 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.015% | 2 | |||||||||||||||||||
| Ingenol Mebutate Gel 0.05% | 0 | |||||||||||||||||||
Six local skin reaction (LSR) signs were predefined and were assessed for presence and intensity at each visit. These included: Erythema, edema, Weeping/Exudate, Flaking/Scaling/Dryness, Scabbing/Crusting and Erosion/Ulceration. The LSRs were scored as 0=none, 1=mild, 2=moderate, 3=severe. Summary of LSR - area under the curve (AUC) of sum of LSR scores (days). (NCT00603798)
Timeframe: The time period for the AUC extends to 8 weeks after the end of treatment (Week 17)
| Intervention | units on a scale * days (Mean) |
|---|---|
| 3.75% Imiquimod Cream | 413.5 |
| 2.5% Imiquimod Cream | 372.0 |
| Placebo Cream | 188.6 |
"Subject status with respect to complete clearance of AK lesions at End of Study (EOS), ie, the Week 17 visit. Complete clearance was defined as the absence of clinically visible or palpable AK lesions in the treatment area. All lesions within the identified treatment area were included in the count, even if the lesion was a new lesion or subclinical lesion that had not been identified at Baseline." (NCT00603798)
Timeframe: End of Study the Week 17 visit
| Intervention | participants (Number) |
|---|---|
| 3.75% Imiquimod Cream | 55 |
| 2.5% Imiquimod Cream | 41 |
| Placebo Cream | 9 |
Subject status with respect to complete clearance of AK lesions at End of Study (EOS), defined as at least a 75% reduction in the number of AK lesions in the treatment area compared with Baseline. (NCT00603798)
Timeframe: End of Study the Week 17 visit
| Intervention | participants (Number) |
|---|---|
| 3.75% Imiquimod Cream | 87 |
| 2.5% Imiquimod Cream | 70 |
| Placebo Cream | 21 |
Percent change from Baseline to end of study (EOS) in investigator counts of AK lesions. A negative percent change is better than a positive percent change. (NCT00603798)
Timeframe: At all visits - Baseline through the Week 17 EOS visit
| Intervention | percentage of participants (Median) |
|---|---|
| 3.75% Imiquimod Cream | -80.0 |
| 2.5% Imiquimod Cream | -66.7 |
| Placebo Cream | -23.6 |
Six local skin reaction (LSR) signs were predefined and were assessed for presence and intensity at each study visit. These included: Erythema, Edema, Weeping/Exudate, Flaking/Scaling/Dryness, Scabbing/Crusting and Erosion/Ulceration. The LSRs were scored as 0=none, 1=mild, 2=moderate, 3=severe. Mean scores were summated over time (14 weeks) to yield a mean LSR AUC (area under the curve) (NCT00605176)
Timeframe: At all visits - from Baseline to End of study (Week 14)
| Intervention | units on a scale * days (Mean) |
|---|---|
| 3.75% Imiquimod Cream | 272.0 |
| 2.5% Imiquimod Cream | 242.5 |
| Placebo Cream | 139.8 |
Subject status with respect to complete clearance of AK lesions at End of Study (EOS), ie, the Week 14 visit. Complete clearance was defined as the absence of clinically visible or palpable AK lesions in the treatment area. All lesions within the identified treatment area were included in the count, even if the lesion was a new lesion or 'subclinical' lesion that had not been identified at Baseline. (NCT00605176)
Timeframe: End of Study the Week 14 visit
| Intervention | participants (Number) |
|---|---|
| 3.75% Imiquimod Cream | 57 |
| 2.5% Imiquimod Cream | 49 |
| Placebo Cream | 10 |
Subject status with respect to partial clearance of AK lesions at end of study (EOS), defined as at least a 75% reduction in the number of AK lesions in the treatment area compared with Baseline. (NCT00605176)
Timeframe: End of Study the Week 14 visit
| Intervention | participants (Number) |
|---|---|
| 3.75% Imiquimod Cream | 95 |
| 2.5% Imiquimod Cream | 77 |
| Placebo Cream | 36 |
Percent change from Baseline to end of study (EOS) in investigator counts of AK lesions. (NCT00605176)
Timeframe: From baseline to End of Study the Week 14 visit
| Intervention | percent change (Median) |
|---|---|
| 3.75% Imiquimod Cream | -81.8 |
| 2.5% Imiquimod Cream | -71.8 |
| Placebo Cream | -25.0 |
The primary efficacy variable in this study was the absence of AK lesions(sustained clearance rate) in the previously treated area. (NCT00668733)
Timeframe: Up to one year
| Intervention | participants (Number) |
|---|---|
| 2-Week Treatment Group | 52 |
| 3-Week Treatment Group | 41 |
11 reviews available for salicylic acid and Keratosis, Actinic
| Article | Year |
|---|---|
Improving the efficacy of photodynamic therapy for actinic keratosis: A comprehensive review of pharmacological pretreatment strategies.
Topics: Aminolevulinic Acid; Diclofenac; Fluorouracil; Humans; Keratosis, Actinic; Photochemotherapy; Photos | 2023 |
New Topical Treatment Options for Actinic Keratosis: A Systematic Review.
Topics: Administration, Cutaneous; Aminoquinolines; Dermatologic Agents; Diterpenes; Drug Combinations; Faci | 2016 |
Low-Dose 0.5% 5-Fluorouracil/10% Salicylic Acid Topical Solution in the Treatment of Actinic Keratoses.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Humans; | 2016 |
Tirbanibulin for the Treatment of Actinic Keratosis: A Review.
Topics: Acetamides; Administration, Topical; Humans; Keratosis, Actinic; Morpholines; Pyridines; Scalp; Trea | 2022 |
Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Topics: Adjuvants, Immunologic; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Dic | 2020 |
Therapeutic Options for the Treatment of Actinic Keratosis with Scalp and Face Localization.
Topics: Carcinoma in Situ; Carcinoma, Squamous Cell; Decision Making; Face; Humans; Keratosis, Actinic; Prec | 2020 |
Daylight photodynamic therapy: experience in the treatment of actinic keratosis in the San Gallicano Institute (Rome) and a review of literature.
Topics: Aged; Aged, 80 and over; Cohort Studies; Face; Female; Humans; Keratosis, Actinic; Male; Middle Aged | 2020 |
Prevalence, Discontinuation Rate, and Risk Factors for Severe Local Site Reactions with Topical Field Treatment Options for Actinic Keratosis of the Face and Scalp.
Topics: Administration, Topical; Antineoplastic Agents; Carcinoma, Squamous Cell; Face; Humans; Keratosis, A | 2019 |
A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.
Topics: Aminolevulinic Acid; Clinical Trials as Topic; Europe; Face; Humans; Keratosis, Actinic; Photochemot | 2014 |
A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.
Topics: Europe; Face; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agents; Scalp | 2016 |
Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Combined Modality Therapy; Cryos | 2011 |
40 trials available for salicylic acid and Keratosis, Actinic
| Article | Year |
|---|---|
Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double-blind, vehicle-controlled trial.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Double-Blind Method; Female; Fluorouracil; Hu | 2018 |
A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Cryosurgery; Drug Combinations; Facial Dermatose | 2015 |
Efficacy of low-dose 5-fluorouracil/salicylic acid in actinic keratoses in relation to treatment duration.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; D | 2015 |
Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid--pilot study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Combinations; F | 2010 |
Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofe | 2011 |
Randomized controlled trial for evaluation of efficacy and pain during photodynamic therapy for actinic keratosis of face and scalp comparing two irradiation protocols.
Topics: Aminolevulinic Acid; Face; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Age | 2022 |
Efficacy of two different methods of cold air analgesia for pain relief in PDT of actinic keratoses of the head region - a randomized controlled comparison study.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Agents; S | 2022 |
The impact of occlusive vs non-occlusive application of 5-aminolevulinic acid (BF-200 ALA) on the efficacy and tolerability of photodynamic therapy for actinic keratosis on the scalp and face: A prospective within-patient comparison trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Face; Female; Gels; Humans; Keratosis, Actinic; Male; | 2021 |
Efficacy and safety of ingenol disoxate gel in field treatment of actinic keratosis on full face, scalp or large area (250 cm2) on the chest: results of four phase 3 randomized controlled trials.
Topics: Administration, Cutaneous; Aged; Dermatologic Agents; Diterpenes; Face; Female; Gels; Humans; Kerato | 2020 |
Comparative study of imiquimod 3.75% vs. photodynamic therapy for actinic keratosis of the scalp.
Topics: Aminolevulinic Acid; Humans; Imiquimod; Keratosis, Actinic; Male; Photochemotherapy; Photosensitizin | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Topics: Acetamides; Administration, Topical; Aged; Double-Blind Method; Enzyme Inhibitors; Face; Female; Hum | 2021 |
A randomized split-face clinical trial of conventional vs indoor-daylight photodynamic therapy for the treatment of multiple actinic keratosis of the face and scalp and photoaging.
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agents; Scalp; | 2022 |
Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Area Under Curve; Arm; Diterpenes; Face; Female; | 2018 |
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest.
Topics: Administration, Topical; Aged; Diterpenes; Dose-Response Relationship, Drug; Face; Female; Humans; K | 2017 |
Conventional vs. daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12-month follow-up results of a randomized, intra-individual comparative analysis.
Topics: Aged; Aged, 80 and over; Face; Female; Follow-Up Studies; Humans; Keratosis, Actinic; Male; Middle A | 2018 |
Calcipotriol as pretreatment prior to daylight-mediated photodynamic therapy in patients with actinic keratosis: A case series.
Topics: Adult; Aged; Aminolevulinic Acid; Calcitriol; Dermatologic Agents; Face; Female; Humans; Keratosis, | 2018 |
Protoporphyrin IX formation after application of methyl aminolevulinate on the face and scalp with and without prior curettage.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Face; Female; Humans; Keratosis, Actinic; M | 2018 |
Short incubation fractional CO
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carc | 2019 |
A randomized intraindividual comparative study of methyl-5-aminolaevulinate vs. 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) in photodynamic therapy for actinic keratosis of the face and scalp.
Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Erythema; Face; Female; Humans; Keratosis, Act | 2018 |
Photodynamic therapy for actinic keratosis of the forehead and scalp: a randomized, controlled, phase II clinical study evaluating the noninferiority of a new protocol involving irradiation with a light-emitting, fabric-based device (the Flexitheralight p
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Facial Dermatoses; Female; Forehead; Humans; Keratosis | 2019 |
Single versus two-treatment schedule of methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient randomized trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Drug Administration Schedule; Face; Female; Humans; Ke | 2019 |
The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: summary of the scientific assessment of the Committee for Medicinal Products for Human Us
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Face; Fema | 2014 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aminoquinolines; Dose-Response Relationship | 2013 |
Topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid: randomized controlled trial with six months follow-up.
Topics: Aminolevulinic Acid; Face; Follow-Up Studies; Humans; Keratosis, Actinic; Photochemotherapy; Photose | 2014 |
Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
Topics: Administration, Cutaneous; Aged; Combined Modality Therapy; Cryosurgery; Dermatologic Agents; Diterp | 2014 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Dose-Response Relationship, Drug; Double-Blind Metho | 2014 |
Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Delayed-Action Preparations; | 2015 |
Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.
Topics: Aged; Aminoquinolines; Antineoplastic Agents; Double-Blind Method; Face; Facial Dermatoses; Female; | 2015 |
Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial.
Topics: Administration, Oral; Aged; Aminolevulinic Acid; Analgesia; Analgesics, Opioid; Analysis of Variance | 2015 |
A Randomized Split-Face Clinical Trial of Photodynamic Therapy with Methyl Aminolevulinate versus Ingenol Mebutate Gel for the Treatment of Multiple Actinic Keratoses of the Face and Scalp.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Diterpenes; Face; Facial Derm | 2016 |
Variables in Cryosurgery Technique Associated With Clearance of Actinic Keratosis.
Topics: Administration, Cutaneous; Adolescent; Adult; Cryosurgery; Dermatologic Agents; Diterpenes; Face; Ge | 2017 |
PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Arm; A | 2009 |
Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facia | 2010 |
Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anticarcinogenic Agents; Cyclooxygenase 1; Cyclo | 2010 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Do | 2010 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Do | 2010 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Do | 2010 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Do | 2010 |
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Do | 2010 |
Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
Topics: Aged; Aged, 80 and over; Alopecia; Aminoquinolines; Face; Female; Half-Life; Humans; Imiquimod; Kera | 2010 |
Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream.
Topics: Adult; Aminoquinolines; Double-Blind Method; Drug Administration Schedule; Face; Humans; Imiquimod; | 2011 |
Single vs. fractionated photodynamic therapy for face and scalp actinic keratoses: a randomized, intraindividual comparison trial with 12-month follow-up.
Topics: Aged; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Male; Middle Aged; Photochemotherapy; | 2012 |
Treatment of actinic keratoses and photodamage with non-contact fractional 1540-nm laser quasi-ablation: an ex vivo and clinical evaluation.
Topics: Aged; Cicatrix; Edema; Erythema; Face; Female; Humans; Keratosis, Actinic; Laser Therapy; Lasers, So | 2013 |
59 other studies available for salicylic acid and Keratosis, Actinic
| Article | Year |
|---|---|
Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study.
Topics: Fluorouracil; Humans; Keratosis, Actinic; Prospective Studies; Salicylic Acid; Treatment Outcome | 2022 |
Treatment monitoring of 5-fluorouracil 0.5%/salicylic acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy.
Topics: Dermoscopy; Fluorouracil; Humans; Keratosis, Actinic; Microscopy, Confocal; Salicylic Acid | 2020 |
0.5% 5-Fluorouracil/10% Salicylic Acid for the Treatment of Distal Actinic Keratoses Under Daily Practice Conditions
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Dermatologic Agents; Drug Combinations; Extremit | 2019 |
Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain.
Topics: Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Cryotherapy; Decision Support Techniques; Dr | 2015 |
In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%/salicylic acid 10% in actinic keratosis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dermatologic Agen | 2015 |
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Topics: Cost-Benefit Analysis; Cryotherapy; Diclofenac; Diterpenes; Dose-Response Relationship, Drug; Fluoro | 2016 |
Retrospective analysis evaluating the effect of a keratolytic and physical pretreatment with salicylic acid, urea and curettage on the efficacy and safety of photodynamic therapy of actinic keratoses with methylaminolaevulinate.
Topics: Aged; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Male; Middle Aged; Photochemotherapy; | 2016 |
Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy.
Topics: Administration, Topical; Dermoscopy; Drug Administration Schedule; Drug Therapy, Combination; Female | 2016 |
Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses.
Topics: Administration, Topical; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; Keratosi | 2016 |
Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorour | 2017 |
The cost-effectiveness of 5-FU-SA in the treatment of actinic keratoses of the face and scalp in the UK secondary care setting.
Topics: Aged; Cost-Benefit Analysis; Face; Humans; Keratolytic Agents; Keratosis, Actinic; Male; Salicylic A | 2017 |
[Effect of sodium para-amino-salicylate on disorders of keratinization].
Topics: Amino Acids; Aminosalicylic Acid; Humans; Keratosis; Keratosis, Actinic; Salicylic Acid; Sodium; Sod | 1950 |
Encountering Ethylene Vinyl Alcohol in Dimethyl Sulfoxide Embolization Material During Electrodesiccation and Curettage.
Topics: Aged, 80 and over; Animals; Arteriovenous Fistula; Biopsy; Carcinoma in Situ; Curettage; Dimethyl Su | 2021 |
No room for pain: A prospective study showing effective and nearly pain-free treatment of actinic keratosis with simulated daylight photodynamic therapy (SDL-PDT) using the IndoorLux® System in combination with BF-200 ALA (Ameluz®).
Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Pain; Photochemotherapy; Photosensitizing Agents; P | 2022 |
Efficacy and safety of a thermal fractional skin rejuvenation system (Tixel) for the treatment of facial and/or scalp actinic keratoses.
Topics: Humans; Keratosis, Actinic; Prospective Studies; Rejuvenation; Scalp; Skin; Treatment Outcome | 2022 |
Fully home-based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study.
Topics: Aged; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Male; Photochemotherapy; Photosensiti | 2022 |
IGF1 synthesis after CO
Topics: Aged; Carbon Dioxide; Carcinoma, Squamous Cell; Humans; Insulin-Like Growth Factor I; Keratosis, Act | 2023 |
Association between calcium channel blockers and the severity of actinic keratosis on face and scalp: a cross-sectional study.
Topics: Calcium Channel Blockers; Cross-Sectional Studies; Humans; Keratosis, Actinic; Male; Scalp; Skin Neo | 2023 |
[Multiple cutaneous squamous cell carcinoma after treatment with ingenol mebutate].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; | 2019 |
Iceberg sign in actinic keratosis neglecta caused by toning shampoo for blonde and white hair.
Topics: Biopsy; Dermoscopy; Hair Preparations; Humans; Keratosis, Actinic; Scalp; Skin | 2020 |
Combined daylight and conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis of the face and scalp: a new and efficient approach.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Face; Female; Humans; Keratosis, Actinic; Light; Male; | 2020 |
Surgical approach to the management of field cancerization: Own experience.
Topics: Carcinoma, Squamous Cell; Humans; Keratosis, Actinic; Scalp; Skin; Skin Neoplasms | 2020 |
Clinical, histopathological and immunohistochemical evaluation of daylight photodynamic therapy in the treatment of field cancerization: a study of 30 cases.
Topics: Adult; Aminolevulinic Acid; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agents; | 2022 |
Occurrence of Acute Cerebellar Syndrome After Topical Application of Fluorouracil.
Topics: Acute Disease; Administration, Topical; Cerebellar Diseases; Fluorouracil; Humans; Immunosuppressive | 2017 |
A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity.
Topics: Face; Humans; Keratosis; Keratosis, Actinic; Photography; Reproducibility of Results; Scalp; Severit | 2017 |
Field treatment of actinic keratosis on the scalp.
Topics: Humans; Keratosis; Keratosis, Actinic; Scalp; Scalp Dermatoses | 2017 |
Ingenol mebutate for the treatment of actinic keratosis: effectiveness and safety in 246 patients treated in real-life clinical practice.
Topics: Administration, Topical; Adult; Age Factors; Aged; Aged, 80 and over; Diterpenes; Face; Female; Gels | 2018 |
Response to 'Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp'.
Topics: Diclofenac; Diterpenes; Humans; Keratosis, Actinic; Scalp | 2018 |
Response to 'Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp': reply from the authors.
Topics: Diclofenac; Diterpenes; Humans; Keratosis, Actinic; Scalp | 2018 |
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up.
Topics: Diclofenac; Diterpenes; Follow-Up Studies; Humans; Keratosis, Actinic; Scalp | 2018 |
Histological intralesional heterogeneity of actinic keratoses relates to field cancerization.
Topics: Aged; Aged, 80 and over; Biopsy; Cell Proliferation; Cell Transformation, Neoplastic; Facial Neoplas | 2018 |
Two cases of erosive pustular dermatosis of the scalp occurring after topical 3.75% imiquimod for actinic keratoses.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Clobetasol; Dermatologic Agents; Drug Eruptions; | 2019 |
Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparis
Topics: Administration, Topical; Aged; Aged, 80 and over; Diterpenes; Dose-Response Relationship, Drug; Face | 2019 |
Daylight photodynamic therapy in 25 patients with actinic keratosis and evaluation of efficacy by confocal microscopy.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Face; Female; Humans; Keratosis, Actinic; Male; Micros | 2019 |
Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the scalp in immunosuppressed patients: our case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Erythema; Female; Humans; Imiquimod; Immunocompromis | 2020 |
Taking daylight-PDT home.
Topics: Aminolevulinic Acid; Germany; Humans; Keratosis, Actinic; Photochemotherapy; Scalp | 2019 |
Come in from the cold - laser fabric photodynamic therapy offers an alternative to seasonal daylight therapy.
Topics: Aminolevulinic Acid; Forehead; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizing Agent | 2019 |
The '5R + R' Rule: A simple and comprehensive method for diagnosis of actinic keratosis.
Topics: Education, Medical, Continuing; Humans; Keratosis, Actinic; Scalp | 2019 |
Ablative Fractional Laser-assisted Daylight Photodynamic Therapy for Actinic Keratoses of the Scalp and Forehead in Organ Transplant Recipients: A Pilot Study.
Topics: Aged; Aminolevulinic Acid; Female; Forehead; Humans; Keratosis, Actinic; Male; Middle Aged; Photoche | 2019 |
5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Bandages; Carcinoma, Squamous Cell; Fluo | 2013 |
Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer.
Topics: Aged; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Deoxyribod | 2013 |
Monitoring treatment of field cancerisation with 3% diclofenac sodium 2.5% hyaluronic acid by reflectance confocal microscopy: a histologic correlation.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Diclofenac; Drug Therapy | 2015 |
Comparative study of trichloroacetic acid vs. photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp.
Topics: Administration, Topical; Aged, 80 and over; Aminolevulinic Acid; Child; Humans; Keratosis, Actinic; | 2015 |
Ablative fractional laser intensifies treatment outcome of scalp actinic keratoses with ingenol mebutate: a case report.
Topics: Diterpenes; Humans; Keratosis, Actinic; Laser Therapy; Male; Scalp; Treatment Outcome | 2016 |
Effect of Field Treatment of Actinic Keratosis With Ingenol Mebutate Gel on the Identification of Lesions for Biopsy.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Combined Modality Therapy; Cryosurger | 2015 |
Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Cohort Studies; Dermatologic Agent | 2018 |
Sequential Curettage, 5-Fluorouracil, and Photodynamic Therapy for Field Cancerization of the Scalp and Face in Solid Organ Transplant Recipients.
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Ther | 2016 |
Scalp melanoma: Distinctive high risk clinical and histological features.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ear Neoplasms; Facial Neoplasms; Female; Head and Neck | 2017 |
Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Double-Blind Method; Face; F | 2016 |
Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study.
Topics: Administration, Cutaneous; Adult; Diterpenes; Face; Female; Humans; Keratosis, Actinic; Male; Retros | 2016 |
A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe: response to comments from Prof Dirschka.
Topics: Europe; Face; Humans; Keratosis, Actinic; Network Meta-Analysis; Photochemotherapy; Scalp; Treatment | 2017 |
Response to: a network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.
Topics: Europe; Face; Humans; Keratosis, Actinic; Network Meta-Analysis; Scalp | 2017 |
Ingenol Mebutate 500 μg for Treatment of the Scalp in Refractory Field Cancerization.
Topics: Aged; Antineoplastic Agents; Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diterp | 2016 |
Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time.
Topics: Aminolevulinic Acid; Face; Humans; Keratosis, Actinic; Male; Middle Aged; Pain; Photochemotherapy; P | 2017 |
Intensified inflammatory reaction of actinic keratoses after single application of topical 5-fluorouracil in a patient treated with nilotinib for chronic myeloid leukemia.
Topics: Administration, Cutaneous; Aged; Antineoplastic Agents; Dermatologic Agents; Drug Therapy, Combinati | 2009 |
Scalp problems.
Topics: Alopecia; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Medical Illustration; Photography; Psor | 2010 |
[Malignant skin diseases in organ transplant patients].
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Humans; Immunosuppressive | 2012 |
[COMBINED THERAPY OF CORNU CUTANEUM OF THE SCALP].
Topics: Cornus; Humans; Keratosis; Keratosis, Actinic; Radiotherapy; Scalp; Scalp Dermatoses; Skin Neoplasms | 1964 |
Dermabrasion of extensive keratotic lesions of the forehead and scalp.
Topics: Dermabrasion; Dermatologic Surgical Procedures; Disease; Face; Forehead; Humans; Keratosis; Keratosi | 1962 |